Type / Class
Equity / American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share
Shares outstanding
41,123,390
Number of holders
19
Total 13F shares, excl. options
17,597,059
Shares change
-1,187,725
Total reported value, excl. options
$137,080,000
Value change
-$11,368,450
Number of buys
5
Number of sells
-17
Price
$7.79

Significant Holders of Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) as of Q3 2021

32 filings reported holding ACHL - Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share as of Q3 2021.
Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 17,597,059 shares of 41,123,390 outstanding shares and own 42.79% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (5,014,687 shares), BAKER BROS. ADVISORS LP (2,591,366 shares), Artal Group S.A. (2,255,375 shares), Redmile Group, LLC (2,088,089 shares), ORBIMED ADVISORS LLC (1,584,845 shares), BOXER CAPITAL, LLC (1,536,016 shares), PERCEPTIVE ADVISORS LLC (755,375 shares), Point72 Asset Management, L.P. (500,000 shares), FARALLON CAPITAL MANAGEMENT LLC (450,000 shares), and AXA S.A. (279,454 shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.